Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.23.3
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents [note 6] $ 19,919 $ 24,771
Grant receivable [note 3] 83 105
Prepaid expenses and other assets 1,895 2,454
Total current assets 21,897 27,330
Right-of-use assets [note 9] 80 66
Other assets and restricted cash [note 6] 74 123
License agreement [note 4 and note 5] 1,252 1,418
Goodwill [note 5] 1,034 1,034
Total assets 24,337 29,971
Current liabilities:    
Accounts payable 638 1,660
Accrued liabilities other 693 403
Accrued clinical liabilities 990 1,729
Accrued compensation 1,700 1,678
Current portion of long-term obligations [note 9] 61 58
Convertible debt [note 6 and note 7]   16,071
Total current liabilities 4,082 21,599
Convertible debt [note 7] 16,195  
Long-term obligations [note 9] 22 69
Total liabilities 20,299 21,668
Commitments and contingencies [note 9]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 21,165,760 issued and outstanding at September 30, 2023 and 17,897,029 issued and outstanding at December 31, 2022 90 87
Additional paid-in capital 164,219 144,148
Accumulated deficit (160,275) (135,936)
Accumulated other comprehensive income 4 4
Total stockholders' equity 4,038 8,303
Total liabilities and stockholders' equity 24,337 29,971
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value